Cochrane · systematic review · CD005109
Recombinant human interleukin 10 for induction of remission in Crohn's disease
Buruiana, FE, Solà, I, Alonso‐Coello, P · Cochrane Database of Systematic Reviews · 2010 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 100%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
IL‐10 compared to placebo for induction of remission in Crohn's disease
Population: patients with induction of remission in Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete remission (CDAI<150 with a decrease in CDAI of at least 100 points from baseline) IL‐10 vs placebo | RR 1.43 [0.62, 3.29] | 3 studies · 470 participants | Moderate Downgraded: imprecision, inconsistency |
Clinical remision (CDAI<150) IL‐10 vs placebo | RR 1.29 [0.79, 2.11] | 3 studies · 470 participants | Moderate Downgraded: imprecision |
Withdrawls due to adverse events IL‐10 vs placebo | RR 13.5 [3.89, 46.79] | 2 studies · 228 participants | Moderate Downgraded: imprecision |